Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyPharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitisOral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsActivities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patientsCultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones.Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model.Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infectionPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves.Levofloxacin pharmacokinetics in adult cystic fibrosis.Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral AdministrationActivity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposurePharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi modelA new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesPharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
P2860
Q24519008-FA447CC7-C352-4602-B44A-34388C85D86EQ33699541-E5D869DD-3965-41FF-8993-1666F9EDA9E1Q33720333-5E494E43-DB43-4558-97DC-4FBA38EB4135Q33767602-CDDFA0E7-E647-4A68-863E-25C75F2D6E1AQ33978925-DFD84A42-8C2E-45F2-9D61-231851A566BBQ33982098-A409786A-9F54-47B2-9925-6DBFD4FD3543Q33983228-026E102B-79D3-416D-86C0-8ADE0360F264Q34042257-7B374D63-A440-4BB6-8FB1-5A481F101CF1Q34108406-F1AE9BC5-CC5F-4B36-B828-CE1D66846E88Q34110906-95C62BD3-975A-47A1-88BE-EA9BE35C2D6FQ34297656-CA0FE6E7-9200-43F6-9663-64856D32493AQ34509676-764BF25F-BD24-41FA-953B-02D46F80BDAEQ34680572-0B73B423-3409-4D70-B002-FBBD7BF0A203Q35685485-A005535F-7246-417A-8087-F83645FA99D0Q35884208-341F8671-74F0-4B5E-83C6-496AF6C57037Q36137356-2BC46672-7ABE-483C-8493-0E2D26D12425Q37115679-3CCC676F-9BE3-477B-BB38-1244157EF2EAQ37568933-18F730D1-155F-4F2E-A4C4-093AA0F2CF41Q38581416-8712E94F-920E-4C1C-A7D0-6E93BC635C4BQ39471111-C636DD85-16CE-4D7B-9507-E27D307DE612Q39471750-91AADEAB-024D-4B87-BBD0-54873963F50CQ39478611-24402A79-B89B-46E5-8102-DC2AB673D024Q39557221-0FF3B299-D75A-4800-9AD9-B1676375891DQ39558024-22954D62-A62B-45B9-A4A1-4E4FEB72B60CQ39559370-BB8D385C-5198-476F-8686-0C789C6B86E4Q39650985-5BD6D42B-4D09-4EBE-B764-45614949EAD8Q39731788-35F721F5-E1B2-4DE8-AE8C-BB7CE392A92DQ39746394-CAE6EABA-D918-4AB6-904C-60026BD147EFQ40621865-82B88BB4-5E3C-4D3C-A4B1-9285365F1D34Q42408718-A261CE22-5F8F-4863-B522-51821F5FD35C
P2860
Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@en
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@nl
type
label
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@en
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@nl
prefLabel
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@en
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@nl
P2093
P2860
P1476
Twenty-four-hour area under th ...... n vitro pharmacodynamic model.
@en
P2093
Madaras-Kelly KJ
Ostergaard BE
Rotschafer JC
P2860
P304
P407
P577
1996-03-01T00:00:00Z